Overview

Welchol as Monotherapy for Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Colesevelam Hydrochloride